Asthma Classification
Asthma is classified into four severity categories based on a systematic assessment of symptom frequency, nighttime awakenings, short-acting beta-agonist (SABA) use, lung function (FEV₁ or PEF), and activity limitation: intermittent, mild persistent, moderate persistent, and severe persistent. 1
Classification Framework
The classification system uses two domains that must be assessed together 1:
1. Impairment Domain (Current Clinical Control)
Evaluate these parameters before initiating treatment:
- Symptom frequency: How often symptoms occur during the day
- Nighttime awakenings: Frequency of nocturnal symptoms requiring awakening
- SABA use for symptom relief: Days per week requiring rescue inhaler (not including pre-exercise prophylaxis)
- Activity limitation: Interference with normal daily activities
- Lung function: FEV₁ or PEF as percentage of predicted normal
2. Risk Domain (Future Adverse Outcomes)
- Exacerbation frequency requiring oral corticosteroids
- Progressive loss of lung function
- Risk of treatment side effects
Specific Severity Categories
Intermittent Asthma
- Symptoms: ≤2 days/week
- Nighttime awakenings: ≤2 times/month
- SABA use: ≤2 days/week
- Activity limitation: None
- Lung function: FEV₁ or PEF ≥80% predicted 2
Mild Persistent Asthma
- Symptoms: >2 days/week but not daily
- Nighttime awakenings: 3-4 times/month
- SABA use: >2 days/week but not daily
- Activity limitation: Minor limitation
- Lung function: FEV₁ or PEF ≥80% predicted 2
Moderate Persistent Asthma
- Symptoms: Daily
- Nighttime awakenings: >1 time/week but not nightly
- SABA use: Daily
- Activity limitation: Some limitation
- Lung function: FEV₁ or PEF 60-79% predicted 1, 2
Severe Persistent Asthma
- Symptoms: Throughout the day (continuous)
- Nighttime awakenings: Often 7 times/week (nightly)
- SABA use: Several times per day
- Activity limitation: Extremely limited
- Lung function: FEV₁ or PEF <60% predicted 1, 2
Critical Implementation Points
Severity classification is primarily used for initial treatment decisions before starting controller therapy 1. The classification determines which step of pharmacologic therapy to initiate.
Key Measurement Requirements
Spirometry is mandatory in all patients ≥5 years of age to objectively confirm airflow obstruction and its reversibility 1. Peak flow measurements alone are insufficient for initial diagnosis but useful for ongoing monitoring.
Demonstrate ≥20% variability in PEF (either improvement after bronchodilator or decline during symptomatic periods) to establish definitive asthma diagnosis 2.
Common Pitfalls to Avoid
Point-in-time assessments systematically underestimate disease severity 3. Research shows that patients meeting criteria for moderate-severe persistent asthma at baseline spent only 71% of treatment weeks in the moderate category, with substantial week-to-week variability 3. This variability means:
- Single office visit assessments may miss true disease burden
- Patients require assessment over multiple weeks
- Relying solely on current symptoms leads to inadequate therapy
Assign severity based on the most severe category in which ANY feature occurs 1. If a patient has infrequent daytime symptoms but frequent nighttime awakenings, classify according to the nighttime awakening frequency.
After Treatment Initiation
Once controller therapy begins, switch from assessing "severity" to monitoring "control" 1. Control assessment uses similar parameters but guides treatment adjustments (stepping up or down therapy) rather than initial classification.
The distinction matters because severity reflects disease intensity before treatment, while control reflects treatment response. A patient with severe persistent asthma can achieve well-controlled status with appropriate therapy.